Skip to content

Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria

Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004074
Enrollment
Unknown
Registered
2020-11-23
Start date
2020-11-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The diagnosis was IgA nephropathy, and the pathologic reports of renal perforation were reported in all cases; 2. No gender limitation, aged 18-70 years; 3. Moderate proteinuria(24-hour urinary protein quantity is between 1.0-2.5g)accompanied or not accompanied by microscopic hematuria; 4. CKD1-2 (GFR>=60ml/min/1.73m2); 5. TCM syndrome differentiation accords with qi deficiency and blood stasis syndrome as well as wind pathogen and heat toxicity; 6. Non-dialysis patients with infection, acidosis, electrolyte disturbance, hypertension and other aggravating factors are effectively controlled and the condition is stable. The BP is between 130-90/80-60mmHg. Potassium is in the normal range; 7. Voluntarily accept this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary factors leading to proteinuria, such as purpura nephritis, lupus nephritis; 2. Patients who have been treated by glucocorticoid, immunosuppressant, tripterygium wilfordii preparation in three months are not included; 3. Having mental illness, infectious disease or lactation, pregnancy or planned pregnancy during the study period; 4. Patients complicated with serious diseases of the heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival; 5. Patients with unilateral or bilateral renal artery stenosis; 6. Participants who are participating in other interventional clinical trials.

Design outcomes

Primary

MeasureTime frame
Urine protein quantitation for 24 hours;

Secondary

MeasureTime frame
Routine urine;TCM symptom score;Blood fat;renal function;

Countries

China

Contacts

Public ContactZhang Yu

Xiyuan Hospital, China Academy of Chinese Medical Sciences

zhangyu8225@126.com+86 13611079831

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026